Relay Therapeutics, Inc. (RLAY)
| Market Cap | 4.04B +606.4% |
| Revenue (ttm) | 10.68M +39.0% |
| Net Income | -272.71M |
| EPS | -1.57 |
| Shares Out | 217.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,573,926 |
| Open | 17.62 |
| Previous Close | 17.83 |
| Day's Range | 17.62 - 18.76 |
| 52-Week Range | 3.03 - 18.94 |
| Beta | 1.74 |
| Analysts | Strong Buy |
| Price Target | 24.82 (+33.73%) |
| Earnings Date | Aug 6, 2026 |
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R... [Read more]
Financial Performance
In 2025, Relay Therapeutics's revenue was $15.36 million, an increase of 53.44% compared to the previous year's $10.01 million. Losses were -$276.48 million, -18.13% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $24.82, which is an increase of 33.73% from the latest price.
News
Relay Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Zovega’s clinical programs in breast cancer and vascular anomalies are advancing, with strong efficacy and safety data supporting ongoing and planned phase III trials. Oral dosing and selective mechanisms provide competitive advantages, while regulatory and commercial strategies target accelerated approvals and broad market access.
Relay Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Three pivotal data sets were presented, including an oral regimen with 11-month PFS in breast cancer and paradigm-shifting results in vascular anomalies. Rapid trial progress, strong financials, and regulatory engagement support near-term advancement in both oncology and rare disease markets.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies f...
Relay Therapeutics price target raised to $26 from $22 at Guggenheim
Guggenheim raised the firm’s price target on Relay Therapeutics (RLAY) to $26 from $22 and keeps a Buy rating on the shares. The firm updated its model for recent financing…
Relay Therapeutics price target raised to $28 from $25 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Relay Therapeutics (RLAY) to $28 from $25 and keeps a Buy rating on the shares after the company presented initial results from…
Relay Therapeutics 22.9M share Secondary priced at $12.00
The deal size was increased to $275M from $175M and priced below last closing price of $13.02. Jefferies, TD Cowen, Goldman Sachs, Guggenheim and Raymond James are acting as joint…
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies f...
Relay Therapeutics price target raised to $21 from $19 at Citizens
Citizens raised the firm’s price target on Relay Therapeutics (RLAY) to $21 from $19 and keeps an Outperform rating on the shares. Relay Therapeutics reported top-line data showing that zovegalisib…
Relay Therapeutics price target raised to $27 from $21 at Barclays
Barclays raised the firm’s price target on Relay Therapeutics (RLAY) to $27 from $21 and keeps an Overweight rating on the shares. The company’s zovegalisib clinical update positioned the drug…
Relay Therapeutics announces $175M common stock offering
Relay Therapeutics (RLAY) announced that it has commenced an underwritten public offering of $175M of shares of its common stock. All of the shares in the proposed offering are to…
Relay Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies f...
Relay Therapeutics upgraded at JonesResearch after zovegalisib data
As previously reported, JonesResearch upgraded Relay Therapeutics (RLAY) to Buy from Hold with a price target of $20, up from $18, stating that the firm is “highly encouraged” by the…
Relay Therapeutics upgraded to Buy from Hold at JonesResearch
JonesResearch upgraded Relay Therapeutics (RLAY) to Buy from Hold.
Relay Therapeutics rises 8.6%
Relay Therapeutics (RLAY) is up 8.6%, or $1.04 to $13.14.
Relay Therapeutics price target raised to $26 from $23 at Raymond James
Raymond James raised the firm’s price target on Relay Therapeutics (RLAY) to $26 from $23 and keeps a Strong Buy rating on the shares. Relay Therapeutics reported highly encouraging initial…
TD Cowen sees Relay’s Phase 2 zovegalisib data ‘a best-case scenario’
Commenting on Relay Therapeutics (RLAY)’ initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies, TD Cowen says it is “best case scenario” with 65% unconfirmed…
Why Is Relay Therapeutics Stock (RLAY) Up Today?
Relay Therapeutics stock rallied on Tuesday alongside positive early results from a Phase 2 trial.
Relay Therapeutics up 11% in pre-market after zovegalisib update
Shares of Relay Therapeutics (RLAY) are up 11% in pre-market trading at $13.45 after the company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular…
Relay Therapeutics Transcript: Status update
Initial data for zovegalisib in vascular anomalies show high response rates and favorable safety, with 100% volumetric response at 300 mg BID and robust symptomatic improvement. Expansion cohorts are open, regulatory discussions are ongoing, and the addressable U.S. market is estimated at $6–8 billion.
Relay Therapeutics Press release: Status update
Relay Therapeutics issued a press release on May 19, 2026, disclosing material business information to investors.
Relay Therapeutics Slides: Status update
Relay Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Relay Therapeutics’ zovegalisib shows potential efficacy in vascular anomalies
Relay Therapeutics (RLAY) announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kalpha mutant-selective inhibition. Vascul...
Relay's treatment shown to shrink vascular malformations in mid-stage trial
Relay Therapeutics said on Tuesday a mid-stage trial showed its experimental treatment can shrink vascular malformations and improve symptoms in patients with rare vascular disorders.
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population in 2L breast cancer